Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report). The company’s shares closed yesterday at $7.85.

Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, Codexis, and Repligen. According to TipRanks, Hewitt has an average return of -3.5% and a 41.75% success rate on recommended stocks.

Currently, the analyst consensus on Maravai Lifesciences Holdings is a Strong Buy with an average price target of $10.50, implying a 33.76% upside from current levels. In a report released on April 22, Robert W. Baird also maintained a Buy rating on the stock with a $8.00 price target.

Based on Maravai Lifesciences Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $66.87 million and a GAAP net loss of $6.46 million. In comparison, last year the company earned a revenue of $204.71 million and had a net profit of $37.63 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Maravai Lifesciences Holdings (MRVI) Company Description:

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company’s segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers’ research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.